Ibogaine for Anxiety Disorders

2 papers and 0 clinical trials exploring ibogaine as a treatment for anxiety disorders.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile

Indication300 million worldwide

Anxiety Disorders

Anxiety disorders, affecting around 300 million people globally, are among the most prevalent mental health conditions. Emerging clinical research suggests that various psychedelics, including psilocybin, MDMA, and LSD, hold potential for alleviating anxiety symptoms through innovative therapeutic approaches.

Full Anxiety Disorders profile

Academic Research

2 papers

Paywallindividual

An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress

In mice subjected to unpredictable mild stress, a single dose of the psychedelic analogue tabernanthalog (TBG) reduced anxiety and rescued deficits in sensory processing and cognitive flexibility. TBG achieved this by promoting regrowth of excitatory dendritic spines, lowering baseline neuronal activity and restoring stimulus‑dependent responses in somatosensory cortical circuits.

Published: May 25, 2021
Journal: Molecular Psychiatry
Authors: Cameron, L. P., Cao, B., Chen, L., Lu, J., Lukasiewicz, K., Mullen, B., Olson, D. E., Shah-Morales, S., Tjia, M., Weiser, S., Zuo, Y.

Open Accessindividual

Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans

In a retrospective survey of 51 U.S. Special Operations Forces veterans who completed a psychedelic programme in Mexico (ibogaine and 5‑MeO‑DMT), participants reported very large reductions in suicidal ideation, PTSD, depression, anxiety and cognitive impairment alongside large increases in psychological flexibility. These preliminary, self‑reported findings are limited by retrospective design and lack of randomisation/blinding, so controlled trials are needed to establish efficacy.

Published: July 8, 2020
Journal: Chronic Stress
Authors: Amoroso, T., Averill, L. A., Barsuglia, J. P., Davis, A. K., Sepeda, N. D.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Anxiety Disorders yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Anxiety Disorders trials Full Ibogaine profile Full Anxiety Disorders profile